SCHEMBL7073312

SCHEMBL7073312

CC(=N)N1CCc2[nH]c(Cc3nc4ccc(C(=O)NCCc5cccc6ccccc56)cc4n3C)nc2C1

nearest known ligand 0.38

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
TRPV1 Q8NER1 1/20 0.37
GAA P10253 1/20 0.37
OPRM1 P35372 1/20 0.36
OPRD1 P41143 1/20 0.36
OPRK1 P41145 1/20 0.36
MAPT P10636 5/20 0.36
TP53 P04637 4/20 0.36
TDP1 Q9NUW8 1/20 0.36
LMNA P02545 1/20 0.36
ACSS2 Q9NR19 1/20 0.36
MTNR1A P48039 2/20 0.35
HDAC1 Q13547 1/20 0.35
HDAC6 Q9UBN7 1/20 0.35
HTR6 P50406 2/20 0.34
POLB P06746 1/20 0.34
DGAT2 Q96PD7 1/20 0.34
NQO2 P16083 1/20 0.34
MTNR1B P49286 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7074863 0.93 GAA (0.36) GAAMAPTTP53LMNAACSS2
SCHEMBL7068238 0.93 TRPV1 (0.36) TRPV1GAAOPRM1OPRD1OPRK1
SCHEMBL7068242 0.93 TRPV1 (0.36) TRPV1GAAOPRM1OPRD1OPRK1
SCHEMBL7071876 0.90 TRPV1 (0.37) TRPV1GAAOPRM1OPRD1OPRK1
SCHEMBL7072504 0.90 GAA (0.38) GAAACSS2HDAC1HDAC6POLB
SCHEMBL7075741 0.89 TGM2 (0.38) GAAMAPTTP53TDP1LMNA
SCHEMBL7075048 0.87 ACSS2 (0.38) ACSS2HDAC1HDAC6
SCHEMBL7072215 0.86 OPRM1 (0.36) TRPV1OPRM1OPRD1OPRK1MAPT
SCHEMBL7072285 0.86 SMN1; SMN2 (0.40) MAPTTP53LMNAHDAC1HDAC6
SCHEMBL7073496 0.85 NPC1 (0.46) TP53ACSS2HDAC6POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 US claimed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 US claimed
EP-1019382-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS, INC. (US) 2000-07-19 EP claimed
WO-1998045275-A1 COMPOUNDS AND COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH SERINE PROTEASE, PARTICULARLY TRYPTASE, ACTIVITY AXYS PHARMACEUTICALS CORPORATION (US) 1998-10-15 WO claimed
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders AXYS PHARMACEUTICALS, INC. (US) 2003-11-13 US disclosed
US-6562854-B2 Antiinflammatory agents; respiratory system disorders AXYS PHARMACEUTICALS, INC. 2003-05-13 US disclosed
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity Celera Corporation 2001-12-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010053779-A1 Novel compounds and compositions for treating diseases asociated with protease activity CMA1, CPA3, TPSG1 TRPV1 823/4885GAA 69/4885OPRM1 1725/4885
US-20030212120-A1 Compositions comprising a substituted benzimidazole useful for treating immunomediated inflammatory disorders CMA1, TPSG1, TPSD1 TRPV1 954/4885GAA 181/4885OPRM1 1617/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.